Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 3

Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty

NCT03774836 · tracked via the Priya Life Science USA tracker
Sponsor
Avenue Therapeutics, Inc
Phase
Phase 3
Started
2018-12-14
Last updated
2019-05-09

Condition(s) studied

Pain Management

Investigational drug(s) / intervention(s)

Tramadol →Morphine →Placebo

Tramadol: IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Morphine: Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Placebo: Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Study summary

This study is evaluating the analgesic efficacy of intravenous (IV) tramadol (AVE-901) compared to placebo in the management of postoperative pain following abdominal surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The patient is male or female 18-75 years of age * Willing to give consent and able to understand the study procedures * Female patients must be of non-childbearing potential or be practicing a highly effective contraption * The patient must be willing to be housed in a healthcare facility and able to receive parenteral analgesia for at least 48 hours after surgery * The patient meets definition of American Society of Anesthesiologists (ASA) Physical Class 1, or 2. Exclusion Criteria: * The patient is undergoing an abdominoplasty of significant complexity defined as pre-planned surgical time of greater than 180 mins. * The patient has a recent (within 5 years) and/or current history of chronic analgesic, opiate or tranquilizer abuse or dependence or is a user of illicit drugs or has had a recent history (within 2 years) of drug or alcohol abuse. * The patient is taking herbal or dietary supplements or medications that are moderate or strong inhibitors of CYP2D6 or CYP3A4 (e.g., fluoxetine, paroxetine, amitriptyline, quinidine, ketoconazole, erythromycin, grapefruit juice) or inducers of CYP3A4 (e.g., carbamazepine, rifampin, St. John's Wort) and cannot go through a minimum washout period of 14 days prior to surgery. * The patient has a history of epilepsy, is susceptible to seizures. * The patient cannot be withdrawn from medications (at least 7 days prior to surgery) that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans, cyclobenzaprine triptans). * The patient has had a recent cardiovascular event or clinically significant abnormal ECG finding at screening or baseline. * The patient has a history of Long QT Syndrome or a relative with this condition. * The patient has expressed suicidal ideation or is considered to be at risk of suicide. * The patient is morbidly obese (body mass index \[BMI\] ≥ 40 kg/m2) or has documented sleep apnea requiring CPAP or other treatment. * Female patient is pregnant and/or undergoing a pregnancy-related surgery, or breastfeeding. * The patient has a history of cardiopulmonary, neurological or psychiatric or other medical condition that may confound the assessments of efficacy or safety. * The patient has cirrhosis, moderate or severe hepatic impairment or an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \> 3X upper limit of normal (ULN) at Screening. * The patient has severe renal impairment or a serum creatinine value of \> 2.0 mg/dL at Screening. * The patient has potassium, sodium, calcium or magnesium levels outside of the normal range or any other clinically significant abnormalities in laboratory values at Screening.

Primary outcome measure(s)

  • The Sum of Pain Intensity Differences through 24 hours — 24 hours post dose

Trial sites (3)

FacilityCityRegionStatus
Lotus Clinical Research Pasadena California
Hermann Drive Research Houston Texas
Endeavor Clinical Trials San Antonio Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03774836 on ClinicalTrials.gov ↗ ← All trials in the USA